Luminex Beats On Assay Boost
Posted on February 07, 2012 at 08:25 AM EST
Luminex Corporation (NASDAQ:LMNX), a developer of biological testing technologies, reported fourth-quarter fiscal 2011 adjusted earnings of 11 cents a share, outpacing both the Zacks Consensus Estimate and the year-ago earnings of 7 cents a share. The adjusted earnings exclude costs associated with the company’s acquisition of EraGen Biosciences. Profit rose 7.6% year over year to [...]

Luminex Corporation (NASDAQ:LMNX), a developer of biological testing technologies, reported fourth-quarter fiscal 2011 adjusted earnings of 11 cents a share, outpacing both the Zacks Consensus Estimate and the year-ago earnings of 7 cents a share. The adjusted earnings exclude costs associated with the company’s acquisition of EraGen Biosciences.
Profit rose 7.6% year over year to $3.4 million (or 8 cents a share) as the Texas-based company saw double-digit growth in its top line, backed by a … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here